Brokers Set Expectations for AnaptysBio, Inc.’s FY2017 Earnings (ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Research analysts at Wedbush lifted their FY2017 earnings per share (EPS) estimates for AnaptysBio in a report released on Thursday. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will earn ($1.59) per share for the year, up from their previous estimate of ($1.76). Wedbush has a “Positive” rating and a $82.00 price target on the stock. Wedbush also issued estimates for AnaptysBio’s Q4 2017 earnings at ($0.35) EPS, Q1 2018 earnings at ($0.41) EPS, Q2 2018 earnings at ($0.45) EPS, Q3 2018 earnings at ($0.50) EPS, Q4 2018 earnings at ($0.54) EPS, FY2018 earnings at ($1.90) EPS, FY2019 earnings at ($2.19) EPS, FY2020 earnings at ($2.06) EPS and FY2021 earnings at ($0.69) EPS.

Several other research firms have also commented on ANAB. Zacks Investment Research upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price target for the company in a report on Friday. JMP Securities boosted their price target on shares of AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Credit Suisse Group boosted their price target on shares of AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Finally, Royal Bank Of Canada initiated coverage on shares of AnaptysBio in a report on Thursday, September 14th. They issued an “outperform” rating and a $40.00 price target for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. AnaptysBio currently has an average rating of “Buy” and an average price target of $81.00.

COPYRIGHT VIOLATION NOTICE: “Brokers Set Expectations for AnaptysBio, Inc.’s FY2017 Earnings (ANAB)” was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://transcriptdaily.com/2017/11/14/brokers-set-expectations-for-anaptysbio-inc-s-fy2017-earnings-anab.html.

Shares of AnaptysBio (NASDAQ:ANAB) opened at $71.23 on Monday. AnaptysBio has a twelve month low of $15.17 and a twelve month high of $74.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.02.

Several institutional investors have recently modified their holdings of the company. Citadel Advisors LLC purchased a new position in shares of AnaptysBio in the 3rd quarter worth approximately $20,406,000. Artal Group S.A. grew its position in shares of AnaptysBio by 459.4% in the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after buying an additional 205,310 shares during the last quarter. Vanguard Group Inc. grew its position in shares of AnaptysBio by 22.6% in the 2nd quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock worth $4,931,000 after buying an additional 37,932 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of AnaptysBio by 210.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock worth $6,363,000 after buying an additional 124,219 shares during the last quarter. Finally, VHCP Management II LLC purchased a new position in shares of AnaptysBio in the 3rd quarter worth approximately $5,856,000. 59.04% of the stock is currently owned by hedge funds and other institutional investors.

In other news, major shareholder Holdings A/S Novo sold 356,300 shares of AnaptysBio stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $21.10, for a total value of $7,517,930.00. Following the transaction, the insider now owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply